

UCSF

UC San Francisco Previously Published Works

Title

IFN $\gamma$ /IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children

Permalink

<https://escholarship.org/uc/item/4j31t3vq>

Journal

PLOS Pathogens, 10(1)

ISSN

1553-7366

Authors

Jagannathan, Prasanna

Eccles-James, Ijeoma

Bowen, Katherine

et al.

Publication Date

2014

DOI

10.1371/journal.ppat.1003864

Peer reviewed

# IFN $\gamma$ /IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children

Prasanna Jagannathan<sup>1</sup>, Ijeoma Eccles-James<sup>1</sup>, Katherine Bowen<sup>1</sup>, Felistas Nankya<sup>2</sup>, Ann Auma<sup>2</sup>, Samuel Wamala<sup>2</sup>, Charles Ebusu<sup>2</sup>, Mary K. Muhindo<sup>2</sup>, Emmanuel Arinaitwe<sup>2</sup>, Jessica Briggs<sup>1</sup>, Bryan Greenhouse<sup>1</sup>, Jordan W. Tappero<sup>3</sup>, Moses R. Kamya<sup>4</sup>, Grant Dorsey<sup>1</sup>, Margaret E. Feeney<sup>1,5\*</sup>

**1** Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America, **2** Infectious Diseases Research Collaboration, Kampala, Uganda, **3** Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, **4** Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda, **5** Department of Pediatrics, University of California, San Francisco, San Francisco, California, United States of America

## Abstract

Although evidence suggests that T cells are critical for immunity to malaria, reliable T cell correlates of exposure to and protection from malaria among children living in endemic areas are lacking. We used multiparameter flow cytometry to perform a detailed functional characterization of malaria-specific T cells in 78 four-year-old children enrolled in a longitudinal cohort study in Tororo, Uganda, a highly malaria-endemic region. More than 1800 episodes of malaria were observed in this cohort, with no cases of severe malaria. We quantified production of IFN $\gamma$ , TNF $\alpha$ , and IL-10 (alone or in combination) by malaria-specific T cells, and analyzed the relationship of this response to past and future malaria incidence. CD4<sup>+</sup> T cell responses were measurable in nearly all children, with the majority of children having CD4<sup>+</sup> T cells producing both IFN $\gamma$  and IL-10 in response to malaria-infected red blood cells. Frequencies of IFN $\gamma$ /IL10 co-producing CD4<sup>+</sup> T cells, which express the Th1 transcription factor *T-bet*, were significantly higher in children with  $\geq 2$  prior episodes/year compared to children with  $< 2$  episodes/year ( $P < 0.001$ ) and inversely correlated with duration since malaria ( $Rho = -0.39$ ,  $P < 0.001$ ). Notably, frequencies of IFN $\gamma$ /IL10 co-producing cells were not associated with protection from future malaria after controlling for prior malaria incidence. In contrast, children with  $< 2$  prior episodes/year were significantly more likely to exhibit antigen-specific production of TNF $\alpha$  without IL-10 ( $P = 0.003$ ). While TNF $\alpha$ -producing CD4<sup>+</sup> T cells were not independently associated with future protection, the absence of cells producing this inflammatory cytokine was associated with the phenotype of asymptomatic infection. Together these data indicate that the functional phenotype of the malaria-specific T cell response is heavily influenced by malaria exposure intensity, with IFN $\gamma$ /IL10 co-producing CD4<sup>+</sup> T cells dominating this response among highly exposed children. These CD4<sup>+</sup> T cells may play important modulatory roles in the development of antimalarial immunity.

**Citation:** Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, et al. (2014) IFN $\gamma$ /IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children. *PLoS Pathog* 10(1): e1003864. doi:10.1371/journal.ppat.1003864

**Editor:** Jean Langhorne, National Institute for Medical Research, United Kingdom

**Received:** August 22, 2013; **Accepted:** November 19, 2013; **Published:** January 9, 2014

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

**Funding:** This work was supported by the Centers for Disease Control and Prevention (Cooperative Agreement No U62P024421); NIH/NIAID R01AI093615 (MEF), UCSF Centers for AIDS Research (Supplement to MEF, P30AI027763), NIH/NIAID U19AI089674 (GD), NIH/NIAID K23 AI100949 (PJ), and Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene (PJ). Additional support was provided by the National Center for Advancing Translational Sciences/NIH, through UCSF-CTSI Grant Number UL1 TR000004. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the NIH.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: margaret.feeney@ucsf.edu

## Introduction

Clinical immunity to malaria eventually develops in endemic populations, but only after repeated infections with significant morbidity to both individuals and their communities [1]. Studies in regions of high malaria transmission intensity have consistently shown that the incidence of severe disease decreases considerably after the first years of life, but sterile immunity (i.e. protection against parasitemia) develops rarely if ever [2,3]. Moreover, previously immune individuals may lose protection against symptomatic infection in the absence of continuous exposure [4,5]. The reasons underlying the slow acquisition of clinical immunity and the failure to develop sterilizing immunity are unclear, but may include parasite diversity and evasion [6], age-related differences in immune responses [7–12], and/or host immunoregulatory mechanisms

induced by the parasite [13–19]. As the incidence of malaria continues to be high in many parts of Africa despite insecticide-treated bednets and artemisinin-based combination therapy [20–22], there is a tremendous need to better understand mechanisms of immunity to malaria in naturally exposed populations. The identification of immunologic correlates of exposure and protection in naturally exposed children would significantly help with the rational design of vaccines and other malaria control interventions.

Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells have been demonstrated to play an important role in protective antimalarial immunity in mouse models [23–30], and experimental challenge models in humans and mice strongly suggest that malaria-specific T cells contribute to protective immunity [31–36]. However, the identification of T cell correlates of immunity in field-based studies of naturally exposed humans has proven to be quite challenging. Prior studies

## Author Summary

Despite reports of decreasing malaria morbidity across many parts of Africa, the incidence of malaria among children continues to be very high in Uganda, even in the setting of insecticide-treated bednets and artemisinin-based combination therapy. Additional control measures, including a vaccine, are sorely needed in these settings, but progress has been limited by our lack of understanding of immunologic correlates of exposure and protection. T cell responses to malaria are thought to be important for protection in experimental models, but their role in protecting against naturally acquired infection is not clear. In this study, we performed detailed assessments of the malaria-specific T cell response among 4-year-old children living in Tororo, Uganda, an area of high malaria transmission. We found that recent malaria infection induces a malaria-specific immune response dominated by Th1 T cells co-producing IFN $\gamma$  and IL-10, and that these cells are not associated with protection from future infection. IFN $\gamma$ /IL-10 co-producing cells have been described in several parasitic infections and are hypothesized to be important in limiting CD4-mediated pathology, but they may also prevent the development of sterilizing immunity. These observations have important implications for understanding the pathophysiology of malaria in humans and for malaria vaccine development.

employing cross-sectional or prospective cohort designs have found associations between cellular immune responses and protection from future malaria, including IFN $\gamma$  responses to liver stage [37–40] and/or merozoite stage malaria antigens [41–44]. However, such studies may be confounded by the level of exposure to malaria-infected mosquitoes, which varies greatly within populations, leading subjects with lower exposure to be mis-categorized as “protected” [45,46]. Because naturally acquired immunity confers relative rather than absolute protection – manifested by a gradual decline in the incidence of clinical disease – careful quantitative outcome measures are essential, but few population-based studies of natural immunity have included careful measurement of malaria incidence over time.

Pathogen-specific T cells exhibit notable functional heterogeneity, largely dependent on the antigen and cytokine microenvironment encountered during activation, and measurement of a single parameter of T cell function (i.e. IFN $\gamma$  production) may overlook others that are more critical for protection [47]. In other parasitic infections such as leishmania [48,49] and toxoplasma [50], the functional phenotype of the CD4 $^+$  T cell response correlates with the success or failure to clear the pathogen. Recent observations in individuals naturally exposed to malaria suggest an important role for CD4 $^+$  T cell production of TNF $\alpha$ , with or without IFN $\gamma$ , as a potential immunologic correlate of protection [51]. Conversely, CD4 $^+$  T cell production of the regulatory cytokine IL-10 has been implicated in modulating the severity of disease [18,52] and may interfere with the development of protective immunity [14,42,53]. The role of these inflammatory and regulatory cytokines in mediating protective immunity in naturally exposed children, and in determining the balance between immunopathology and chronic repeated infection, remains unknown.

In this study we performed a detailed functional characterization of malaria-specific T cell responses among four-year-old children residing in a highly malaria-endemic region to determine whether naturally acquired T cell responses correlate with

exposure to and/or protection from malaria. We hypothesized that CD4 $^+$  T cells producing the pro-inflammatory cytokines IFN $\gamma$  and/or TNF $\alpha$  are associated with protection from malaria, and that T cell production of the regulatory cytokine IL-10 may interfere with the acquisition of protection. Our results suggest that the functional phenotype of the malaria-specific T cell response was heavily influenced by prior malaria exposure intensity, with CD4 $^+$  T cells co-producing IFN $\gamma$  and IL10 dominating this response among highly exposed children. However, these IFN $\gamma$ /IL-10 co-producing cells were not independently associated with protection from future malaria, and may be associated with increased risk.

## Results

### Study population and clinical outcomes

The study cohort consisted of 78 HIV-uninfected children followed from infancy through 5 years of age (Table 1). Blood for this study was drawn at four years of age (range 49–51 months), and 92% of children continued to be followed through 5 years of age. A total of 1855 incident cases of malaria were observed in this cohort through 5 years of age. All children were treated promptly with artemisinin-based combination therapy, and despite the strikingly high numbers of malaria episodes, only 4 cases of malaria were deemed “complicated” (all based on a single convulsion). No cases of severe malaria (including severe anemia) were observed. Among children with a lower prior incidence of malaria (<2 episodes per person year (ppy) between 1 and 4 years of age, n = 10), 90% lived in town; whereas among children with higher prior malaria incidence ( $\geq$  2 episodes ppy, n = 68), only 7% of children lived in town. This suggests that children with the lowest prior incidence had less exposure to malaria-infected mosquitoes. Episodes of asymptomatic parasitemia were rare in this cohort (median 1 episode per subject over the entire study period, IQR 0–4, Table 1) and the incidence of malaria declined only slightly in the year following the blood draw (from 5.7 to 5.1 episodes ppy), suggesting that effective clinical immunity had not yet emerged in most children. One child had symptomatic malaria (parasitemia with a fever requiring treatment) at the time of the blood draw, and 17 (22%) had blood smears demonstrating parasitemia.

### The functional phenotype of malaria-specific CD4 $^+$ T cells is influenced by prior malaria incidence

To define the frequency and function of malaria-specific T cell responses, PBMC were stimulated with malaria-infected red blood cells (iRBC) and analyzed by flow cytometry for production of IFN $\gamma$ , IL-10, and TNF $\alpha$  (Fig. 1a). The median frequency of malaria-specific CD4 $^+$  T cell responses producing any of these cytokines, alone or in combination, was 0.20% (IQR 0.12%–0.35%). Among all children, frequencies of CD4 $^+$  T cells producing IFN $\gamma$  (median 0.16%) and IL-10 (median 0.14%) were significantly higher than those producing TNF $\alpha$  (median 0.04%,  $P < 0.001$ , Fig. 1b). Production of these two cytokines largely overlapped, with a median of 83% of IL-10-producing cells also making IFN $\gamma$ , and a median of 71% of IFN $\gamma$ -producing cells also making IL-10. Malaria-specific production of IL-2 was tested in a subset of children (n = 44), but responses were consistently of low magnitude (median frequency 0.02%, data not shown). At the time of the assay 17 of the 78 children had positive blood smears; however there was no significant difference in the overall frequency of malaria-specific IFN $\gamma^+$  ( $P = 0.20$ ), TNF $\alpha^+$  ( $P = 0.29$ ), or IL-10 $^+$  ( $P = 0.21$ ) CD4 $^+$  T cells between children with or without parasitemia. Malaria-specific CD8 T cell responses were

**Table 1.** Descriptive statistics of study cohort.

| Characteristic   | Findings         |
|--|------------------|
| Number of children enrolled                                    | 78               |
| Median age in months at time of study enrollment (IQR)         | 5.6 (3.6–7.5)    |
| Person-years observed from enrollment until time of blood draw | 291.6            |
| Median age in months at time of blood draw (IQR)               | 50.9 (48.6–51.4) |
| Person-years observed from blood draw until end of study       | 60.0             |
| Total incident episodes of malaria                             | 1855             |
| Complicated malaria  | 4                |
| Severe malaria   | 0                |
| Median incidence of malaria                                    |                  |
| Prior to blood draw (ppy (IQR))                                | 5.7 (3.9–7.0)    |
| From blood draw to end of study (ppy, IQR)                     | 5.1 (2.5–6.9)    |
| Median days since last episode of malaria (IQR)                | 37 (16–66)       |
| Median days until next episode of malaria (IQR)                | 47 (20–101)      |
| Monthly period prevalence of asymptomatic parasitemia*         |                  |
| Prior to blood draw  | 5%               |
| From blood draw to end of study                                | 11%              |
| Symptomatic malaria at the time of blood draw, n (%)           | 1 (1.2%)         |
| Parasitemia at the time of the blood draw, n (%)               | 17 (22%)         |

Note: IQR, interquartile range.

\*Asymptomatic parasitemia defined as positive routine blood smear in the absence of fever that was not followed by the diagnosis of malaria in the subsequent seven days. Period prevalence calculated as the number of episodes/total months observed.

doi:10.1371/journal.ppat.1003864.t001

not observed in the peripheral blood of any of the 78 children, although this does not exclude their presence in the liver and other tissues as demonstrated by non-human primate studies [54].




The pattern of cytokine production by malaria-specific CD4<sup>+</sup> T cells was noted to differ markedly based on children's prior incidence of malaria (Fig. 2a–c). Both IL-10-producing CD4<sup>+</sup> T cells and IFN $\gamma$ -producing CD4<sup>+</sup> T cells were present at higher frequencies among children with a higher prior incidence of malaria ( $\geq 2$  episodes ppy) than among those with a lower prior incidence ( $< 2$  episodes ppy,  $P < 0.001$  and  $P = 0.02$ , respectively, Fig. 2a). Most strikingly, CD4<sup>+</sup> T cells co-producing IFN $\gamma$  and IL-10 dominated the response among children with higher prior incidence, but were virtually absent among lower incidence children ( $P < 0.001$ , Fig. 2b). Production of TNF $\alpha$  followed the opposite pattern, with higher frequencies of TNF $\alpha$ /IL10<sup>-</sup> CD4<sup>+</sup> T cells observed among children with lower prior incidence than among those with a higher prior incidence ( $P = 0.003$ , Fig. 2b). Interestingly, despite these differences in cytokine production profiles, the overall frequency of malaria-specific CD4<sup>+</sup> T cells (i.e. those producing any cytokine) did not statistically differ between the higher and lower incidence groups ( $P = 0.13$ ).

We also analyzed the relationship of prior malaria incidence with the “composition” of the malaria-specific response (i.e. the proportion of each cytokine combination amongst the total malaria-specific CD4<sup>+</sup> T cell population), and found similar results. Among children with  $< 2$  episodes ppy, TNF $\alpha$ -producing CD4<sup>+</sup> T cells (including TNF $\alpha$  single-producers and IFN $\gamma$ /TNF $\alpha$  double producers) comprised a greater proportion of the malaria-specific response than among children with  $\geq 2$  prior episodes ppy, whereas in children with a higher prior malaria incidence, IL-10-producing CD4<sup>+</sup> T cells (including IL-10 single-producers and IFN $\gamma$ /IL-10 double producers) comprised a far greater fraction of the malaria-specific response ( $P < 0.001$ , Fig. 2c). There was no

significant difference in the proportion of IFN $\gamma$ -producing CD4<sup>+</sup> T cells between children with higher and lower incidence. These findings suggest that the functional phenotype of the malaria-specific CD4<sup>+</sup> T cell response differs according to prior exposure, and that with more prior episodes, the overall response is more regulatory (IL-10 producing) and less inflammatory (TNF $\alpha$  producing).

#### IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells correlate with recent malaria exposure

While the data above demonstrate that there is a strong relationship between the functional phenotype of malaria-specific CD4<sup>+</sup> T cells and prior malaria history, we wished to determine whether this phenotype was influenced by the time elapsed since the most recent malaria episode, the cumulative number of prior malaria episodes, or both, as these parameters are both logically and statistically related (Spearman's  $Rho = -0.46$ ,  $P < 0.001$ ). We observed a strong inverse correlation between the frequency of IFN $\gamma$ <sup>+</sup>/IL-10<sup>+</sup>/TNF $\alpha$ <sup>-</sup> CD4<sup>+</sup> T cells and the duration since the last episode of malaria (Spearman's  $Rho = -0.39$ ,  $P < 0.001$ , Fig. 3d), with more recent malaria associated with a higher frequency of these co-producing cells, as well as a positive correlation with the total cumulative number of prior episodes (Spearman's  $Rho = 0.23$ ,  $P = 0.04$ , Fig. 3e). However, when assessed in a multivariate model, the frequency of malaria-specific IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells remained strongly associated with the duration since malaria, whereas the total prior incidence was no longer significant. Similar results were observed for total IL-10 (Fig. 3a) and total IFN $\gamma$ -producing (Fig. 3b) populations, and when assessing the duration since last episode of parasitemia (data not shown). Interestingly, the opposite relationship was observed between total TNF $\alpha$ <sup>+</sup> producing cells and the



**Figure 1. T cell responses to malaria-infected red blood cells using multiparameter flow cytometry.** A. Gating strategy to identify live CD3<sup>+</sup>γδ<sup>-</sup> T cells. B. Intracellular cytokine assay demonstrating the T cell response of one representative malaria-exposed child to Pf-infected RBC (iRBC; bottom row), with negative controls (uRBC and media) and positive control (PMA/Io) shown in rows above. Shown are CD8 (first column) and CD4 (right 3 columns) production of IFNγ (y-axis, columns 1–3), TNFα (x-axis, columns 1–2; y-axis, column 4), and IL-10 (x-axis, column 3–4). C. The overall malaria-specific CD4<sup>+</sup> T cell response (left column) is followed by the overall frequency of CD4<sup>+</sup> T cells producing IFNγ, IL-10, and TNFα in all participants (n=78, horizontal black lines indicate the median response for each group, \*\*\* P<0.001, Wilcoxon Rank-Sum). doi:10.1371/journal.ppat.1003864.g001

duration since last episode of malaria, with more recent malaria associated with a lower frequency of TNFα<sup>-</sup> producing cells (Spearman's  $Rho = 0.23$ ,  $P = 0.041$ , Fig. 3c). Further, there was no significant correlation between the number of cumulative prior malaria episodes and TNFα<sup>+</sup> producing cells. Together these data suggest that recency of malaria infection, rather than the total number of past episodes, exerts a dominant influence on the functional phenotype of malaria-specific CD4<sup>+</sup> T cells. Similar findings were obtained when analyzing the “composition” (i.e. the proportion of responding cells producing IFNγ, TNFα, and/or IL10) of the malaria-specific response and duration since last malaria infection.

### Malaria-specific CD4<sup>+</sup> T cells are not independently associated with protection from malaria

Protection from clinical malaria in naturally exposed individuals can be defined using a number of outcomes, including a delayed time to reinfection [37,38,41–43,51], a decreased incidence of malaria over time [53], and/or a decreased probability of clinical disease once parasitemic [46]. In all cases, identification of immune correlates of protection is challenging due to the difficulty of distinguishing protection from a lack of exposure to malaria-infected mosquitoes [45,46]. To address this, we assessed the relationship between malaria-specific T cell functional subsets and protection from malaria, while adjusting for prior malaria (duration since last episode and/or cumulative number of prior episodes) as a surrogate measure of exposure intensity. We also evaluated potential associations with the overall prevalence of asymptomatic parasitemia, as clinical immunity to malaria is normally characterized by a transition from symptomatic to asymptomatic disease [3].

In univariate Cox proportional hazards analysis evaluating time to next episode of malaria, a higher frequency of CD4<sup>+</sup> T cells producing any IFNγ or IL10, or the combinations IFNγ<sup>+</sup>/IL-10<sup>+</sup>/TNFα<sup>-</sup> and IFNγ<sup>-</sup>/IL-10<sup>+</sup>/TNFα<sup>-</sup> was associated with a significantly increased hazard of malaria (Table 2, left columns). However following adjustment for surrogates of exposure intensity (duration since last episode of malaria and/or cumulative prior malaria episodes) in a multivariate model, none of these associations remained significant. Similar relationships were observed when we analyzed the total malaria incidence in the year following the assay in a multivariate regression model (Table 2, middle columns). However, in this analysis both IFNγ<sup>+</sup>/IL-10<sup>+</sup>/TNFα<sup>-</sup> (IRR 1.40 per 10 fold increase,  $P = 0.038$ ) and any IL-10-producing CD4<sup>+</sup> T cells (IRR 1.41 per 10 fold increase,  $P = 0.039$ ) remained independently associated with an increased risk of malaria after controlling for duration since last malaria infection. Nearly identical results were obtained when analyzing the total composition of cytokine producing cells: both the fraction of IFNγ<sup>+</sup>/IL-10<sup>+</sup>/TNFα<sup>-</sup> and any IL10<sup>+</sup> cells among all cytokine-producing cells were associated with increased malaria risk (IRR 1.47,  $P = 0.038$  and 1.40,  $P = 0.039$  per 50% increase in fraction of responding cells, respectively). Together, these data suggest that the dominant population of malaria-specific CD4<sup>+</sup> cells, which co-produce IFNγ and IL-10, are not associated with protection from

future malaria, and may in fact be associated with an increased risk of malaria.

We next assessed the relationship of TNFα<sup>-</sup> producing CD4<sup>+</sup> T cells with protection. In RTS/S vaccine recipients, malaria-specific CD4<sup>+</sup> T cells producing TNFα in the absence of IFNγ or IL-2 have recently been shown to correlate with protection from malaria infection [55]. In our cohort, a greater frequency of malaria-specific CD4<sup>+</sup> T cells producing TNFα alone (IFNγ<sup>-</sup>/IL-10<sup>-</sup>/TNFα<sup>+</sup>) was associated with a significantly reduced hazard of developing malaria (HR 0.31,  $P = 0.015$  per 10 fold increase) and lower prospective incidence (IRR 0.44,  $P = 0.004$  per 10 fold increase) in univariate analysis, but in multivariate models controlling for duration since malaria and/or cumulative prior malaria episodes, these associations were no longer significant (Table 2). Interestingly, however, the frequency of malaria-specific CD4<sup>+</sup> T cells producing any TNFα was inversely associated with the monthly prevalence of asymptomatic parasitemia, even after controlling for duration since last episode of malaria and/or cumulative prior malaria episodes (PRR 0.41 per 10 fold increase,  $P = 0.011$ ). Thus, the absence of malaria-specific CD4<sup>+</sup> T cells producing TNFα may be associated with the phenotype of asymptomatic infection.


### IFNγ/IL-10 co-producing cells express *T-bet* and are of an effector memory phenotype

Although IL10 production by T cells was initially believed to occur predominantly within Th2 and FoxP3<sup>+</sup> T<sub>reg</sub> CD4<sup>+</sup> T cell subsets, it is now known that additional subsets, including cells expressing the Th1 master regulator *T-bet*, produce IL-10 under conditions of continuous antigen exposure [56,57]. We assessed transcription factor expression within the dominant population of malaria-specific IFNγ/IL-10 co-producing cells (Fig. 4a) and found that these cells uniformly were TBet<sup>+</sup> and FoxP3<sup>-</sup> (Fig. 4b–c). These IFNγ/IL-10 co-producing CD4<sup>+</sup> T cells were predominantly of an early effector memory phenotype (CD45RA<sup>-</sup>, CCR7<sup>-</sup> CD27<sup>+</sup>; Fig. 4d–e).


CD4<sup>+</sup> T cell IFNγ/IL-10 responses to the polyclonal mitogen PMA/Io have previously been shown to correlate with relative protection against severe malaria [52]. We therefore compared the response to iRBC and PMA/Io stimulation, and found a strong correlation between the frequency of IFNγ/IL-10 double producing CD4<sup>+</sup> T cells following iRBC or PMA stimulation (Spearman's  $Rho = 0.88$ ,  $P < 0.001$ , Supplemental Fig. S1). As PMA/Io stimulation is thought to induce cytokine production by recently activated cells, these data suggest that this mitogen stimulates cytokine production by malaria-specific T cells that have recently seen their cognate antigen.

### Plasma IL-10 levels are elevated during malaria infection but do not correlate with the frequency of IL-10 producing CD4<sup>+</sup> T cells

IL-10 levels measured concurrently in plasma were significantly higher among children with parasitemia at the time of the blood draw compared with children with no parasitemia (median 30.4 pg/ml vs 11.4 pg/ml,  $P = 0.0035$ ), consistent with prior



**Figure 2. Prior malaria incidence influences function of malaria-specific CD4<sup>+</sup> T cell response.** A. The overall malaria-specific CD4<sup>+</sup> T cell response (left column) is followed by the overall frequency of CD4<sup>+</sup> T cells producing IFN<sub>γ</sub>, IL-10, and TNF<sub>α</sub> stratified by prior malaria incidence. Blue dots represent responses from children with lower prior malaria incidence (<2 episodes ppy, n = 10) and red dots represent responses from children with higher prior malaria incidence (≥2 episodes ppy, n = 68, \* P<0.05, \*\*\* P<0.001, Wilcoxon Rank-Sum). Horizontal black lines indicate the median response for each group). Median frequencies of cytokine producing cells were similar in children with ≥2–5 and >5 episodes ppy (data not shown). B–C. Boolean gating of malaria-specific CD4<sup>+</sup> T cells reveals 7 distinct cytokine-producing populations. Shown are the absolute frequency (B) and the relative proportion (C) of each individual combination of IFN<sub>γ</sub>, IL-10, or TNF<sub>α</sub>-producing cells. Blue arcs represent total proportion of CD4<sup>+</sup> T cells producing TNF<sub>α</sub>; red arcs represent total proportion of CD4<sup>+</sup> T cells producing IL-10; and green arcs represent total proportion of CD4<sup>+</sup> T cells producing IFN<sub>γ</sub>. The proportion of IFN<sub>γ</sub><sup>-</sup>/IL-10<sup>+</sup>/TNF<sub>α</sub><sup>-</sup> (population 3) producing cells is <0.01% of the total malaria-specific response, and thus does not have a visible corresponding pie slice.  
doi:10.1371/journal.ppat.1003864.g002



**Figure 3. CD4<sup>+</sup> T cell functions and relationship with recent and cumulative malaria infection.** The frequencies of CD4<sup>+</sup> T cells producing any IL-10 (A) and any IFN $\gamma$  (B) are inversely associated with days since last malaria episode (Spearman's  $Rho = -0.39, P < 0.001$ ;  $Rho = -0.23, P = 0.046$ , respectively). Frequencies of CD4<sup>+</sup> T cells producing any TNF $\alpha$  (C) are positively correlated with days since last malaria episode infection (Spearman's  $Rho = 0.23, P = 0.041$ ). Frequencies of IFN $\gamma^+$ /IL-10<sup>-</sup>/TNF $\alpha^-$  CD4<sup>+</sup> T cells are inversely associated with days since last malaria episode (D, Spearman's  $Rho = -0.39, P < 0.001$ ) and positively associated with the cumulative number of episodes in the prior 3 years (E, Spearman's  $Rho = 0.26, P = 0.023$ ). doi:10.1371/journal.ppat.1003864.g003

reports [58–61]. Similar to IL-10 producing CD4<sup>+</sup> T cells, plasma IL-10 strongly correlated with recent malaria (Spearman's  $Rho = 0.30, P = 0.009$ , Supplemental Fig. S2a). However plasma IL-10 levels did not correlate with the frequency of total IL-10


producing CD4<sup>+</sup> T cells (Spearman's  $Rho = 0.11, P = 0.35$ , Supplemental Fig. S2b), suggesting that additional cell types, including cells of the myeloid lineage, may contribute to plasma IL-10 levels during malaria infection [19].

**Table 2. Magnitude of malaria-specific CD4<sup>+</sup> T cell responses and protection from symptomatic malaria.**

|   | Time until malaria |       |               |       | Future incidence of malaria |       |               |              | Prevalence of asymptomatic parasitemia |       |               |              |
|---|--------------------|-------|---------------|-------|-----------------------------|-------|---------------|--------------|--|-------|---------------|--------------|
|   | Univariate         |       | Multivariate* |       | Univariate                  |       | Multivariate* |              | Univariate                             |       | Multivariate* |              |
| % CD4 <sup>+</sup> T cells (Log <sub>10</sub> )       | HR                 | P     | HR            | P     | IRR                         | P     | IRR           | P            | PRR                                    | P     | PRR           | P            |
| 1) IFN $\gamma^+$ /IL-10 <sup>+</sup> /TNF $\alpha^+$ | 1.79               | 0.051 | 1.14          | 0.671 | 1.42                        | 0.085 | 1.29          | 0.134        | 0.51                                   | 0.111 | 0.43          | 0.037        |
| 2) IFN $\gamma^+$ /IL-10 <sup>+</sup> /TNF $\alpha^-$ | 2.22               | 0.001 | 1.73          | 0.083 | 1.65                        | 0.002 | <b>1.40</b>   | <b>0.038</b> | 0.86                                   | 0.703 | 0.74          | 0.482        |
| 3) IFN $\gamma^-$ /IL-10 <sup>+</sup> /TNF $\alpha^+$ | n/a                | n/a   | n/a           | n/a   | n/a                         | n/a   | n/a           | n/a          | n/a                                    | n/a   | n/a           | n/a          |
| 4) IFN $\gamma^-$ /IL-10 <sup>+</sup> /TNF $\alpha^-$ | 1.73               | 0.047 | 1.53          | 0.198 | 1.43                        | 0.059 | 1.24          | 0.216        | 1.63                                   | 0.247 | 1.94          | 0.130        |
| 5) IFN $\gamma^+$ /IL-10 <sup>-</sup> /TNF $\alpha^-$ | 1.32               | 0.365 | 1.24          | 0.532 | 1.02                        | 0.917 | 1.04          | 0.815        | 1.23                                   | 0.649 | 1.30          | 0.567        |
| 6) IFN $\gamma^+$ /IL-10 <sup>-</sup> /TNF $\alpha^+$ | 0.65               | 0.249 | 1.52          | 0.286 | 0.89                        | 0.649 | 1.32          | 0.199        | 0.39                                   | 0.052 | 0.48          | 0.152        |
| 7) IFN $\gamma^-$ /IL-10 <sup>-</sup> /TNF $\alpha^+$ | 0.31               | 0.015 | 1.25          | 0.725 | 0.44                        | 0.004 | 0.73          | 0.297        | 0.43                                   | 0.070 | 0.61          | 0.422        |
| Any IFN $\gamma^+$                                    | 1.84               | 0.039 | 1.74          | 0.091 | 1.44                        | 0.076 | 1.41          | 0.062        | 0.60                                   | 0.28  | .60           | 0.283        |
| Any IL-10 <sup>+</sup>                                | 2.26               | 0.001 | 1.64          | 0.117 | 1.70                        | 0.001 | <b>1.41</b>   | <b>0.039</b> | 1.00                                   | 0.99  | .88           | .787         |
| Any TNF $\alpha^+$                                    | 0.90               | 0.694 | 1.49          | 0.161 | 0.94                        | 0.720 | 1.20          | 0.254        | 1.20                                   | 0.254 | <b>0.38</b>   | <b>0.004</b> |

Note: HR: Hazard Ratio; IRR: incidence rate ratio; PRR: prevalence rate ratio. Numbered rows refer to cell populations described in Figure 2. Associations in row 3 are not applicable because these responses were undetectable.  
\*Multivariate models controlled for duration since last malaria infection. Similar results were obtained when controlling for cumulative episodes over prior 3 years and for the presence or absence of parasitemia.  
doi:10.1371/journal.ppat.1003864.t002





**Figure 4. CD4<sup>+</sup> T cells co-producing IFN $\gamma$  and IL-10 express *T-bet* and are of an early effector memory phenotype.** CD4<sup>+</sup> T cells were analyzed for transcription factor expression and maturational phenotype. Panel 4A shows the proportion of CD4<sup>+</sup> T cells co-producing IFN $\gamma$ /IL-10 in response to iRBC stimulation for one representative child (upper right quadrant) and panel 4B shows intranuclear transcription factor staining with *T-bet* and FoxP3 of all CD4<sup>+</sup> T cells (grey) with IFN $\gamma$ /IL-10 CD4<sup>+</sup> T cells overlaid (4B, blue dots). Panel 4C shows the percentage of iRBC-stimulated IFN $\gamma$ <sup>+</sup>, IL-10<sup>+</sup>, and IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells staining for intranuclear *T-bet* (n=10). CD4<sup>+</sup> T cells were also analyzed for cell surface maturation markers CD45RA (x axis, panels 4D–E), CCR7 (4D), and CD27 (4E). The total CD4<sup>+</sup> T cell population is shown in grey, with IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells overlaid as blue dots.  
doi:10.1371/journal.ppat.1003864.g004


### Impaired malaria-specific CD4<sup>+</sup> T cell proliferation in heavily exposed children is partially reversed by IL-10 blockade

Immunomodulation through downregulation of antigen-specific CD4<sup>+</sup> T cell proliferative responses has been described in the context of several chronic parasitic infections [62–65], as well as chronic viral infections that result in persistent antigenemia [66,67]. We assessed proliferation of malaria-specific CD4<sup>+</sup> T cells by measuring CFSE dilution following stimulation with schizont extract (PfSE) in a subset of children (n = 42). A significant inverse correlation was observed between malaria-specific CD4<sup>+</sup> T cell proliferation and cumulative prior incidence (Spearman's  $Rho = -0.39$ ,  $P = 0.011$ ; Fig. 5a), suggesting that heavy antigen exposure may result in a proliferative defect in malaria-specific CD4<sup>+</sup> T cells. We also observed an inverse correlation between CD4<sup>+</sup> T cell proliferation following PfSE stimulation and the frequency of IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells (Spearman's  $Rho = -0.31$ ,  $P = 0.049$ ). It has previously been suggested that IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells may play an autoregulatory

role through suppression of proliferative responses in an IL-10 mediated manner [68]. We therefore assessed whether *in vitro* IL10 blockade would reverse the observed proliferative defect. The ability of CD4<sup>+</sup> T cells to proliferate in response to PfSE was partially restored in 8 of 9 subjects upon blockade of IL-10 receptor alpha (fold change 1.7,  $P = 0.01$ , Fig. 5b–c), suggesting that the CD4<sup>+</sup> T cell proliferative defect observed in heavily exposed children may be in part due to IL-10 mediated suppression.

### Discussion

In this cohort of young children living in an area of very high transmission intensity in Uganda, very little evidence of clinical immunity had emerged by five years of age. In this setting, the functional phenotype of the malaria-specific CD4<sup>+</sup> T cell response was significantly influenced by prior malaria exposure; with less prior malaria, the overall malaria-specific CD4<sup>+</sup> T cell response was more inflammatory (TNF $\alpha$ -producing), but with heavier



**Figure 5. CD4<sup>+</sup> T cell proliferation impaired in setting of heavy prior exposure.** A. The proliferation fold change (fraction of CFSE-lo cells following PfSE stimulation vs uRBC stimulation) is significantly reduced in children with higher prior malaria exposure ( $\geq 2$  episodes ppy,  $n = 33$ ) vs children with low malaria exposure ( $< 2$  episodes ppy,  $n = 9$ ,  $P = 0.007$ , Wilcoxon Rank Sum. Horizontal lines show medians for each group with 95% CI). B. Impact of IL-10 blockade on CD4<sup>+</sup> T cell proliferation following PfSE stimulation in one representative subject. The left panel shows CFSE dilution following PfSE stimulation with addition of isotype control, and the right panel shows CFSE dilution following PfSE stimulation with addition of anti IL-10 receptor  $\alpha$  blocking antibody. C. Change in the percent of CD4<sup>+</sup> T cells divided following isotype control vs anti IL-10 receptor  $\alpha$  blocking antibody in a subset of 9 children from whom additional cells were available (fold change 1.7,  $P = 0.01$ ). doi:10.1371/journal.ppat.1003864.g005

exposure, the overall malaria-specific response was more regulatory (IL-10 producing). To our knowledge, this is the first study to show that Th1 IFN $\gamma$ /IL-10 co-producing cells constitute the dominant population of CD4<sup>+</sup> T cells responding to malaria in heavily exposed children. Moreover, we found no evidence that these IFN $\gamma$ /IL-10 co-producing cells were associated with protection from future malaria.

Interest in IFN $\gamma$ /IL-10 co-producing Th1 cells has increased in recent years as these cells have been found to be important regulators of the immune response to several infectious, allergic, and autoimmune diseases [18,49,50,52,56,69,70]. In a murine model of *Toxoplasma gondii*, IFN $\gamma$  produced by these cells was shown to be required for pathogen eradication, and concomitant production of IL-10 was vital for the resolution of the inflammatory response and to prevent tissue pathology [50]. However, in a murine model of *Leishmania major*, co-production of IL-10 by Th1 cells prevented pathogen eradication, contributing to chronic infection [49]. These data suggest that IL-10 co-production by Th1 T cells may help prevent immunopathology, but this may come at the cost of chronic pathogen persistence [71].

IL-10 levels are increased during malaria infection [58,59,61] and this regulatory cytokine is thought to play a key role in dampening proinflammatory responses and preventing the development of severe malarial anemia and cerebral malaria [72]. In mice, Th1 cells were elegantly shown to be the major producer of IL-10 and were critical for limiting the pathology associated with malaria infection [18]. T cell production of IL-10 has also been described in reports of human malaria infection [14,52,73–77]. Plebanski and colleagues described a switch in production from IFN $\gamma$  to IL-10 in CD4<sup>+</sup> T cells from Gambian adults stimulated with altered peptide ligands of the circumsporozoite protein, with an associated suppression of proliferative responses *in vitro* [14]. T cells co-producing IFN $\gamma$ /IL-10 following nonspecific PMA/ionomycin stimulation were described in the context of acute malaria infection [73], and were also more abundant among children with uncomplicated rather than severe malaria [52], consistent with a role in modulating inflammation. More recently, Gitau and colleagues described malaria-specific co-production of IFN $\gamma$  and IL-10 following stimulation of CD4<sup>+</sup> T cells with a variety of expressed PIEMP variants, although these co-producing

cells represented a minor fraction of the total antigen-specific CD4<sup>+</sup> T cell response [75]. The potential role that malaria-specific IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cell cells play in mediating or inhibiting protective immunity in humans has not thus far been investigated [77].

We observed that CD4<sup>+</sup> T cells co-producing IFN $\gamma$ /IL-10 dominate the T cell response to malaria in heavily exposed children, and that the overall frequency and proportion of these cells among malaria-specific T cells was strongly correlated with recent exposure to malaria, more so than cumulative prior exposure. These IFN $\gamma$ /IL-10 co-producing cells express *T-bet*, indicating that they have differentiated along the Th1 pathway. The dominance of this functional phenotype among malaria-specific T cells has not previously been reported, and may be related to the unusually high malaria exposure intensity of our cohort, as this cell population was of much lower frequency among children with  $< 2$  malaria episodes per year. Further, frequencies of IL-10-producing and IFN $\gamma$ /IL-10 co-producing cells were not associated with protection from future malaria after controlling for recent and/or cumulative prior malaria, but were instead associated with an increased risk of cumulative malaria in the year following the assay, although this may be due to the inability to fully adjust for the level of environmental exposure to malaria using clinical surrogates such as prior malaria incidence.

We further observed that heavy malaria exposure was associated with a decreased ability of CD4<sup>+</sup> T cells to proliferate in response to malaria antigens, and that this impaired proliferation is partially reversed by IL-10 blockade. These data are consistent with *in vitro* studies of recently activated IL7R<sup>-</sup>, CD25<sup>-</sup>, CD4<sup>+</sup> T cells which co-produce IFN $\gamma$  and IL-10 and limit CD4<sup>+</sup> T cell proliferation through IL-10 dependent mechanisms [68]. In addition, prior studies have shown that IL-10 blockade increases malaria-specific IFN $\gamma$  cytokine production in filaria-coinfected individuals [78] and in cord blood mononuclear cells from neonates born to mothers exposed to malaria [79]. A similar IL-10-dependent functional impairment of CD4<sup>+</sup> T cells has been described in other infections such as HIV that are characterized by chronic high-level antigen stimulation [80,81].

Together, these data are consistent with the hypothesis that IFN $\gamma$ /IL-10 co-producing CD4<sup>+</sup> T cells primarily function to limit

the immunopathology associated with malaria infection – including cerebral malaria, anemia, and death - through autoregulation of CD4<sup>+</sup> T cell proliferation and cytokine production. A similar role has been attributed to IL-10-producing Th1 cells in other parasitic diseases characterized by heavy continuous antigen exposure [49,50], with evidence that IL-10 produced by Th1 effector cells acts through a negative feedback loop to regulate CD4<sup>+</sup> T cell responsiveness, limiting inflammation and tissue pathology at the cost of impaired pathogen clearance [56,71]. It is possible that unmeasured confounders, such as helminthic co-infections, may have been unequally represented in the high and low-incidence groups, particularly as the lower incidence children were more likely to reside in town. However routine deworming was performed in all study subjects every 3–6 months, lessening the likelihood that co-infection with helminths explains our findings. Further studies are needed to determine if IL-10-producing Th1 cells contribute to pathogen persistence, and to the failure of humans to develop sterile protective immunity to malaria.

In addition, we found that children with the fewest prior episodes of malaria were significantly more likely to have malaria-specific production of TNF $\alpha$  without IL-10, and that the absence of this inflammatory cytokine was associated with the phenotype of asymptomatic infection. Studies in murine models have shown that TNF $\alpha$  plays an important role in inhibiting the development of hepatic stages of malaria [82,83]. Importantly, a recent study of RTS/S vaccine recipients identified antigen-specific CD4<sup>+</sup> T cell production of TNF $\alpha$  as a correlate of protection in vaccinees [55]. In contrast to that study, we found no evidence of protection after controlling for prior malaria, though we did observe that asymptomatic infection was inversely associated with the frequency of TNF $\alpha$  producing CD4<sup>+</sup> T cells, independent of prior malaria. Together our data suggest that production of this inflammatory cytokine may decrease with increasing cumulative malaria exposure, enabling a transition to asymptomatic infections.

A notable strength of this study was the availability of comprehensive malaria clinical histories spanning from early infancy to the time of the immunologic assessment, plus one additional year thereafter, which enabled us to assess for T cell correlates of both exposure to and protection from malaria. Several prior studies have reported correlations between T cell responses or IL-10 production and protection from malaria in naturally exposed children [37,42,53], but such studies have generally been unable to adequately account for prior malaria exposure. While we did observe associations, both positive and negative, between malaria-specific CD4<sup>+</sup> T cells of varying functional phenotypes and the risk of future malaria, most of these associations were not significant after adjusting for recent or cumulative prior episodes of malaria, surrogates for the level of ongoing exposure to malaria-infected mosquitos. Hence the failure to account for malaria exposure intensity may lead to spurious associations with protection. Although we did not identify T cell phenotypes that were associated with protection from future malaria, this may be related to the young age of children in this cohort, as there was little evidence that clinical immunity had developed prior to 5 years of age. Future longitudinal studies examining responses in older children and adults, incorporating more precise entomological measurements of malaria exposure, are underway.

In conclusion, among naturally exposed children living in a high endemicity setting, malaria-specific CD4<sup>+</sup> T cells were present in the vast majority of children, and their functional phenotype differed greatly based on the level of prior exposure to malaria, in

particular the duration of time since last infection. IFN $\gamma$ /IL-10 co-producing Th1 cells dominated the CD4<sup>+</sup> T cell response to malaria in these heavily exposed children, but were not associated with protection from future infection. These CD4<sup>+</sup> T cells may play important immunomodulatory roles in the pathogenesis of malaria in childhood.

## Methods

### Study site, participants, and follow-up procedures

Samples for this study were obtained from children enrolled in the Tororo Child Cohort (TCC) in Tororo, Uganda, a rural district in south-eastern Uganda with an entomological inoculation rate (EIR) estimated at 379 infective bites per person year (PPY) in 2012 [20]. Details of this cohort have been described elsewhere, and the sub-study described in this report includes only HIV-uninfected children born to HIV-uninfected mothers [20,84–87]. Briefly, children in the TCC were enrolled at infancy (median 5.5 months of age) and followed for all medical problems at a dedicated study clinic open seven days a week. Monthly assessments were done to ensure compliance with study protocols and perform routine blood smears. All children were prophylactically dewormed with mebendazole every 3–6 months per Ugandan Ministry of Health guidelines [88]. Children who presented with a documented fever (tympanic temperature  $\geq 38.0^{\circ}\text{C}$ ) or history of fever in the previous 24 hours had blood obtained by finger prick for a thick smear. If the thick smear was positive for malaria parasites, the patient was diagnosed with malaria regardless of parasite density, and given artemisinin-based combination therapy for treatment of uncomplicated malaria. Children were followed until 5 years of age unless prematurely withdrawn.

Incident episodes of malaria were defined as all febrile episodes accompanied by any parasitemia requiring treatment, but not preceded by another treatment in the prior 14 days [20]. The incidence of malaria was calculated as the number of episodes per person years (ppy) at risk. Asymptomatic parasitemia was defined as a positive routine blood smear in the absence of fever that was not followed by the diagnosis of malaria in the subsequent seven days, and was reported as a count outcome as it was measured via monthly surveillance. The period prevalence of asymptomatic parasitemia was calculated as the number of episodes/total months observed.

### Ethical approval

Written informed consent was obtained from the parent or guardian of all study participants. The study protocol was approved by the Uganda National Council of Science and Technology and the institutional review boards of the University of California, San Francisco, Makerere University and the Centers for Disease Control and Prevention.

### Sample collection and processing

At approximately 4 years of age, ~6–10 ml of whole blood was obtained from each subject in acid citrate dextrose tubes. Plasma was collected, and peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation (Ficoll-Histopaque; GE Life Sciences). PBMC were cryopreserved in liquid nitrogen and shipped to our laboratory in San Francisco for additional studies.

### Malaria antigens

*Plasmodium falciparum* blood-stage 3D7 parasites were grown by standard methods and harvested at 5–10% parasitemia. Red blood

cells infected with mature asexual stages were purified magnetically, washed, and cryopreserved in glycerolyte prior to use (iRBC). Uninfected RBCs (uRBC) were used as controls. To assess the impact of parasite diversity on T cell responses, responses to iRBCs prepared from 4 distinct Tororo field strains were compared to iRBC prepared from 3D7. Responses to the 4 field strains were very similar, indicating that parasite diversity does not significantly influence the T cell response magnitude (Supplemental Fig. S3). Schizont extracts (PfSE) for use in proliferation assays [89] were prepared by 3 freeze-thaw cycles of iRBC in liquid N<sub>2</sub> for freezing and 37°C water bath for thawing, then resuspended in R10 media and stored at -20°C until use.

### Intracellular cytokine staining

Thawed PBMC were rested overnight in 10% fetal bovine serum (Gibco) and counted prior to stimulation with uRBC, iRBC, media, or phorbol myristate acetate/calcium ionophore (PMA/Io) at  $1 \times 10^6$  cells/condition. An E:T ratio of 1:3 was used with uRBC and iRBC [90]. Anti-CD28 and -CD49d were added for costimulation (0.5 µg/ml, BD Pharmingen). Brefeldin-A and Monensin (BD Pharmingen) were added at 6 hours of incubation at a final concentration of 10 µg/ml to inhibit cytokine secretion. At 24 hours of incubation, cells were washed, fixed and permeabilized per standard protocols (Invitrogen/Caltag; Ebioscience fix/perm reagents used for nuclear transcription factor analysis).

Surface and/or intracellular staining of PBMC was done with standard protocols [91,92] using the following antibodies for the primary analysis: Brilliant violet 650-conjugated CD4 (Biolegend), PerCP-conjugated anti-CD3, APC-H7-conjugated CD8, PE-Cy7-conjugated IFN $\gamma$ , PE-conjugated anti-IL-10, and FITC-conjugated TNF $\alpha$  (BD Pharmingen). Alexa 700-conjugated CD14 and CD19, APC-conjugated anti- $\gamma\delta$  (Biolegend), and Live/dead aqua amine (Invitrogen) were included as exclusion gates to reduce unwanted nonspecific antibody binding when measuring antigen-specific T cell populations [93]. Additional experiments utilized Brilliant violet 421-conjugated anti-IL-2, Brilliant violet 605-conjugated CD45RA, Brilliant violet 710-conjugated CD27 (Biolegend), APC-conjugated CCR7 (R&D Systems); eFluor 660-conjugated T-bet and FITC-conjugated FoxP3 (Ebioscience).

### CFSE proliferation assay

Thawed PBMC were rested for one hour, washed in 10% Human AB media (Gemini), and  $3-6 \times 10^6$  PBMC were labeled with 1 ml of 1.25 µM 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) for seven minutes. CFSE-labeled PBMC were incubated in 96-well, deep-well culture plates (Nunc, Roskilde, Denmark) at a density of  $10^6$  PBMC per well at a final volume of 1 ml for 7 days. In a subset of patients, CFSE-labeled PBMC were incubated with antigen in the presence of IL-10 receptor alpha chain (IL-10R $\alpha$ ) blocking antibody (clone 37607; R&D Systems) or IgG1 isotype control antibody at 10 µg/mL. Antigens tested included media, phytohemagglutinin (PHA; 5 µg/mL; Sigma-Aldrich), uRBC, or PfSE at an E:T ratio of 1:3 schizont equivalents. At day 7 cells were treated with 100 units DNase I (Invitrogen) in culture medium at 37°C for 10 min, washed, and stained with surface antibodies (PerCP-conjugated anti-CD3, APC-H7-conjugated CD8 (BD Pharmingen), Brilliant violet 650-conjugated CD4, Alexa 700-conjugated CD14 and CD19, and APC-conjugated anti- $\gamma\delta$  (Biolegend)) before acquisition.

### Flow cytometry data analysis

Flow cytometry profiles were gated on CD3<sup>+</sup>,  $\gamma\delta$ -negative lymphocytes, and 200,000 to 300,000 events were collected. Samples were analyzed on an LSR2 three laser flow cytometer (Becton Dickinson) with FACSDiva software. Color compensations were performed for each patient's PBMC using beads or samples single stained for each of the fluorochromes used. Data were analyzed using FlowJo (Tree Star, San Carlos, CA) and Pestre (version 1.7)/SPICE (version 5.3; M. Roederer, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD). In experiments with CFSE-labeled cells, the ratio of CFSE-lo cells following PfSE stimulation vs uRBC stimulation was calculated and reported as the proliferation fold change. The FlowJo Proliferation Platform provided additional information about the division characteristics of CD4<sup>+</sup> T cells. To examine the effect of IL-10 blockade on proliferation, these parameters for CD4<sup>+</sup> T cells were generated in samples that had been stimulated with PfSE plus anti-IL-10R $\alpha$  and compared to the values obtained from samples stimulated with PfSE plus isotype control.

### Plasma IL-10

Plasma levels of IL-10 were measured by dual Ab sandwich-ELISA kits, according to manufacturer's instruction (R&D Systems, Minneapolis, MN). Each sample was tested in duplicate, and cytokine concentrations were calculated using a standard curve generated from recombinant cytokines. Cytokine values were expressed as picograms (pg) per milliliter.

### Statistical methods

All statistical analyses were performed using Prism 4.0 (GraphPad), STATA version 12 (College Station), or SPICE v.5.3 (NIAID). Frequencies of malaria-specific cytokine producing T cells (alone or in combination) are reported after background subtraction of the frequency of the identically gated population of cells from the same sample stimulated with control. Background-subtracted responses were considered positive if >0.01% parent population [94]. Comparisons of cytokine frequencies between prior malaria incidence groups were done using the Wilcoxon rank sum test, and the Wilcoxon signed-rank test was used to compare paired data. Statistical analyses of global cytokine profiles (pie charts) were performed by partial permutation tests using the SPICE software [94]. Continuous variables were compared using Spearman correlation. For multivariate regression models, non-normal variables were log-transformed. To allow for nonlinear relationships between clinical exposure variables and immunologic outcomes, we fit linear splines with knots chosen to best represent observed relationships. Associations between immune parameters and time to next malaria episode were evaluated using the Kaplan-Meier product limit formula, and a multivariate cox proportional hazards model was used to adjust for surrogates of malaria exposure found to be associated with these parameters (duration since last episode of malaria and/or cumulative episodes in the prior 3 years). Negative binomial regression was used to estimate associations between immune parameters and the prospective incidence of malaria in the following year (incidence rate ratios, IRR) and prevalence of asymptomatic parasitemia during the entire study period (prevalence rate ratios, PRR), adjusting for prior malaria as above. Two-sided p-values were calculated for all test statistics and  $P < 0.05$  was considered significant.

## Supporting Information

**Figure S1 Relationship between iRBC and PMA/Io stimulation.** The frequency of iRBC-stimulated CD4<sup>+</sup> T cells producing IFN $\gamma$ /IL-10 is strongly correlated with the frequency of PMA/Io-stimulated CD4<sup>+</sup> T cells co-producing these cytokines (Spearman's  $Rho = 0.86$ ,  $P < 0.0001$ ). (EPS)

**Figure S2 Relationship of Plasma IL-10 levels with malaria and CD4<sup>+</sup> T cells.** Plasma IL-10 is inversely associated with days since last episode of malaria (A, Spearman's  $Rho = -0.30$ ,  $P = 0.009$ ). There is no significant association between plasma IL-10 levels and the frequency of IL-10 producing CD4<sup>+</sup> T cells (B, Spearman's  $Rho = 0.11$ ,  $P = 0.35$ ). (EPS)

**Figure S3 T cell responses to malaria-infected red blood cells comparing responses to 3D7 and field isolates.** Intracellular cytokine staining assay demonstrating the CD4<sup>+</sup> T cell response of a malaria-exposed child to several strains of field isolates, with negative control (uRBC), positive control

## References

- Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: more questions than answers. *Nat Immunol* 9: 725–732.
- Marsh K, Kinyanjui S (2006) Immune effector mechanisms in malaria. *Parasite Immunol* 28: 51–60.
- Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, et al. (2013) An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to *Plasmodium falciparum* infection. *Clin Infect Dis* 57: 40–47.
- Deloron P, Chougnet C (1992) Is immunity to malaria really short-lived? *Parasitol Today* 8: 375–378.
- Di Perri G, Solbiati M, Vento S, De Checchi G, Luzzati R, et al. (1994) West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. *Journal of Travel Medicine* 1: 147–151.
- Barry AE, Schultz L, Buckee CO, Reeder JC (2009) Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, *Plasmodium falciparum*. *PLoS ONE* 4: e8497.
- Adkins B (1999) T-cell function in newborn mice and humans. *Immunol Today* 20: 330–335.
- Pass RF, Stagno S, Britt WJ, Alford CA (1983) Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. *J Infect Dis* 148: 953–961.
- Adkins B, Leclerc C, Marshall-Clarke S (2004) Neonatal adaptive immunity comes of age. *Nat Rev Immunol* 4: 553–564.
- Holt PG (2003) Functionally mature virus-specific CD8(+) T memory cells in congenitally infected newborns: proof of principle for neonatal vaccination? *J Clin Invest* 111: 1645–1647.
- Wilson CB, Lewis DB (1990) Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection. *Rev Infect Dis* 12 Suppl 4: S410–420.
- Wilson CB, Lewis DB, English BK (1991) T cell development in the fetus and neonate. *Adv Exp Med Biol* 310: 17–27.
- Ho M, Webster HK, Looareesuwan S, Supanaranond W, Phillips RE, et al. (1986) Antigen-specific immunosuppression in human malaria due to *Plasmodium falciparum*. *J Infect Dis* 153: 763–771.
- Plebanski M, Flanagan KL, Lee EA, Reece WH, Hart K, et al. (1999) Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of *Plasmodium falciparum*. *Immunity* 10: 651–660.
- Walther M, Tongren JE, Andrews L, Korbel D, King E, et al. (2005) Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. *Immunity* 23: 287–296.
- Bejon P, Mwacharo J, Kai O, Todryk S, Keating S, et al. (2007) The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by *Plasmodium falciparum*. *J Immunol* 179: 4193–4201.
- Butler NS, Moeblus J, Pewe LL, Traore B, Doumbo OK, et al. (2012) Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage *Plasmodium* infection. *Nat Immunol* 13: 188–195.
- Freitas do Rosario AP, Lamb T, Spence P, Stephens R, Lang A, et al. (2012) IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. *J Immunol* 188: 1178–1190.
- Freitas do Rosario AP, Langhorne J (2012) T cell-derived IL-10 and its impact on the regulation of host responses during malaria. *Int J Parasitol* 42: 549–555.
- Jagannathan P, Muhindo MK, Kakuru A, Arinaitwe E, Greenhouse B, et al. (2012) Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. *Malar J* 11: 435.
- Roca-Feltrer A, Kwizombe CJ, Sanjoaquin MA, Sesay SS, Faragher B, et al. (2012) Lack of decline in childhood malaria, Malawi, 2001–2010. *Emerging infectious diseases* 18: 272–278.
- Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, et al. (2011) Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. *Lancet Infectious Diseases* 11: 925–932.
- Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. *Nature* 330: 664–666.
- Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, et al. (1989) Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. *Nature* 341: 323–326.
- Rodrigues M, Nussenzweig RS, Zavala F (1993) The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. *Immunology* 80: 1–5.
- Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, et al. (1998) Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. *J Virol* 72: 6907–6910.
- Stephens R, Albano FR, Quin S, Pascal BJ, Harrison V, et al. (2005) Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance. *Blood* 106: 1676–1684.
- Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, et al. (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. *Proc Natl Acad Sci U S A* 105: 14017–14022.
- Overstreet MG, Cockburn IA, Chen YC, Zavala F (2008) Protective CD8 T cells against *Plasmodium* liver stages: immunobiology of an 'unnatural' immune response. *Immunol Rev* 225: 272–283.
- Stephens R, Langhorne J (2010) Effector memory Th1 CD4 T cells are maintained in a mouse model of chronic malaria. *PLoS Pathog* 6: e1001208.
- Nussenzweig RS, Vanderberg J, Most H, Orton C (1967) Protective immunity produced by the injection of x-irradiated sporozoites of *plasmodium berghei*. *Nature* 216: 160–162.
- Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozoite-induced falciparum malaria. *Am J Med Sci* 266: 169–177.
- Hoffman SL, Doolan DL (2000) Malaria vaccines-targeting infected hepatocytes. *Nat Med* 6: 1218–1219.
- Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. (2009) Protection against a malaria challenge by sporozoite inoculation. *N Engl J Med* 361: 468–477.
- Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, et al. (2010) Natural immunization against malaria: causal prophylaxis with antibiotics. *Sci Transl Med* 2: 40ra49.
- Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, et al. (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. *Lancet* 377: 1770–1776.
- Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, et al. (2004) A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite

- protein correlates with protection from natural *Plasmodium falciparum* infection and disease. *Nat Med* 10: 406–410.
38. Todryk SM, Bejon P, Mwangi T, Plebanski M, Urban B, et al. (2008) Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. *PLoS ONE* 3: e2027.
  39. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, et al. (2001) Pre-erythrocytic immunity to *Plasmodium falciparum*: the case for an LSA-1 vaccine. *Trends Parasitol* 17: 219–223.
  40. Hoffman SL, Oster CN, Mason C, Beier JC, Sherwood JA, et al. (1989) Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. *J Immunol* 142: 1299–1303.
  41. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, et al. (1999) Interferon-gamma responses are associated with resistance to reinfection with *Plasmodium falciparum* in young African children. *J Infect Dis* 179: 980–988.
  42. Moormann AM, Sumba PO, Chelimo K, Fang H, Tisch DJ, et al. (2013) Humoral and Cellular Immunity to *Plasmodium falciparum* Merozoite Surface Protein 1 and Protection From Infection With Blood-Stage Parasites. *J Infect Dis* 208: 149–158.
  43. D'Ombrain MC, Robinson IJ, Stanic DI, Taraika J, Bernard N, et al. (2008) Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 47: 1380–1387.
  44. McCall MB, Hopman J, Daou M, Maiga B, Dara V, et al. (2010) Early interferon-gamma response against *Plasmodium falciparum* correlates with interethnic differences in susceptibility to parasitemia between sympatric Fulani and Dogon in Mali. *J Infect Dis* 201: 142–152.
  45. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, et al. (2009) Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. *Infect Immun* 77: 1917–1923.
  46. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, et al. (2011) Antibodies to *Plasmodium falciparum* antigens predict a higher risk of malaria but protection from symptoms once parasitemic. *J Infect Dis* 204: 19–26.
  47. Douek DC, Roederer M, Koup RA (2009) Emerging concepts in the immunopathogenesis of AIDS. *Annual Review of Medicine* 60: 471–484.
  48. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nature medicine* 13: 843–850.
  49. Anderson CF, Oukka M, Kuchroo VJ, Sacks D (2007) CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. *J Exp Med* 204: 285–297.
  50. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, et al. (2007) Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. *J Exp Med* 204: 273–283.
  51. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, et al. (2011) Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01(E) and Protection against *P falciparum* Clinical Malaria. *PLoS ONE* 6: e25786.
  52. Walther M, Jeffries D, Finney OC, Njie M, Ebonyi A, et al. (2009) Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe *Plasmodium falciparum* malaria. *PLoS Pathog* 5: e1000364.
  53. Zhang G, Manaca MN, McNamara-Smith M, Mayor A, Nhabomba A, et al. (2012) Interleukin-10 (IL-10) polymorphisms are associated with IL-10 production and clinical malaria in young children. *Infect Immun* 80: 2316–2322.
  54. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. *Science*.
  55. Olotu A, Moris P, Mwacharo J, Vekemans J, Kimani D, et al. (2011) Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against *P falciparum* clinical malaria. *PLoS ONE* 6: e25786.
  56. Cope A, Le Fric G, Cardone J, Kemper C (2011) The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching. *Trends in Immunology* 32: 278–286.
  57. O'Garra A, Vieira P (2007) T(H)1 cells control themselves by producing interleukin-10. *Nature reviews Immunology* 7: 425–428.
  58. Wenisch C, Parschalk B, Narzt E, Looareesuwan S, Graninger W (1995) Elevated serum levels of IL-10 and IFN-gamma in patients with acute *Plasmodium falciparum* malaria. *Clinical Immunology and Immunopathology* 74: 115–117.
  59. Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, et al. (1994) High levels of circulating IL-10 in human malaria. *Clinical and experimental immunology* 95: 300–303.
  60. Wilson NO, Bythwood T, Solomon W, Jolly P, Yatich N, et al. (2010) Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women. *Infectious Diseases in Obstetrics and Gynecology* 2010: pii: 317430.
  61. Pinzon-Charry A, Woodberry T, Kienzle V, McPhun V, Minigo G, et al. (2013) Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. *J Exp Med* 210: 1635–1646.
  62. O'Connor RA, Jensen JS, Osborne J, Devaney E (2003) An enduring association? Microfilariae and immunosuppression [correction of immunosuppression] in lymphatic filariasis. *Trends Parasitol* 19: 565–570.
  63. Steel C, Guinea A, McCarthy JS, Ottesen EA (1994) Long-term effect of prenatal exposure to maternal microfilaremia on immune responsiveness to filarial parasite antigens. *Lancet* 343: 890–893.
  64. Wammes LJ, Hamid F, Wiria AE, Wibowo H, Sartono E, et al. (2012) Regulatory T cells in human lymphatic filariasis: stronger functional activity in microfilaremics. *PLoS Neglected Tropical Diseases* 6: e1655.
  65. Maizels RM, Yazdanbakhsh M (2003) Immune regulation by helminth parasites: cellular and molecular mechanisms. *Nature reviews Immunology* 3: 733–744.
  66. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, et al. (2001) High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. *Proc Natl Acad Sci U S A* 98: 13878–13883.
  67. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, et al. (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. *J Exp Med* 194: 1395–1406.
  68. Haringer B, Lozza L, Steckel B, Geginat J (2009) Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. *J Exp Med* 206: 1009–1017.
  69. Bousiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, et al. (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. *J Clin Invest* 105: 1317–1325.
  70. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, et al. (2008) In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. *J Exp Med* 205: 2887–2898.
  71. O'Garra A, Vieira P (2007) T(H)1 cells control themselves by producing interleukin-10. *Nat Rev Immunol* 7: 425–428.
  72. Li C, Corraliza I, Langhorne J (1999) A defect in interleukin-10 leads to enhanced malarial disease in *Plasmodium chabaudi* chabaudi infection in mice. *Infect Immun* 67: 4435–4442.
  73. Winkler S, Willheim M, Baier K, Schmid D, Aichelburg A, et al. (1998) Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in *Plasmodium falciparum* malaria. *Infect Immun* 66: 6040–6044.
  74. Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, et al. (2006) Cellular reactivity to the p. *Falciparum* protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. *Am J Trop Med Hyg* 74: 367–375.
  75. Gitau EN, Tuju J, Stevenson L, Kimani E, Karanja H, et al. (2012) T-cell responses to the DBLalpha-tag, a short semi-conserved region of the *Plasmodium falciparum* membrane erythrocyte protein 1. *PLoS ONE* 7: e30095.
  76. Roetynck S, Olotu A, Simam J, Marsh K, Stockinger B, et al. (2013) Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposure. *PLoS ONE* 8: e55195.
  77. Freitas do Rosario AP, Langhorne J (2012) T cell-derived IL-10 and its impact on the regulation of host responses during malaria. *International Journal for Parasitology* 42: 549–555.
  78. Metenou S, Dembele B, Konate S, Dolo H, Coulibaly YI, et al. (2011) Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections. *Journal of immunology* 186: 4725–4733.
  79. Brustoski K, Moller U, Kramer M, Petelski A, Brenner S, et al. (2005) IFN-gamma and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated *Plasmodium falciparum* malaria. *Journal of immunology* 174: 1738–1745.
  80. Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, et al. (2009) IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. *Blood* 114: 346–356.
  81. Brooks DG, Trifilo MJ, Edelman KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. *Nat Med* 12: 1301–1309.
  82. Depinay N, Franetich JF, Gruner AC, Mauduit M, Chavatte JM, et al. (2011) Inhibitory effect of TNF-alpha on malaria pre-erythrocytic stage development: influence of host hepatocyte/parasite combinations. *PLoS ONE* 6: e17464.
  83. Nussler A, Pied S, Goma J, Renia L, Miltgen F, et al. (1991) TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. *International Immunology* 3: 317–321.
  84. Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, et al. (2009) Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. *Malaria Journal* 8: 272.
  85. Sandison TG, Homsy J, Arinaitwe E, Wanzira H, Kakuru A, et al. (2011) Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. *BMJ* 342: d1617.
  86. Vora N, Homsy J, Kakuru A, Arinaitwe E, Wanzira H, et al. (2010) Breastfeeding and the risk of malaria in children born to HIV-infected and uninfected mothers in rural Uganda. *Journal of Acquired Immune Deficiency Syndromes* 55: 253–261.
  87. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, et al. (2009) Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 49: 1629–1637.
  88. (2010) Uganda Clinical Guidelines 2010. National Guidelines on Management of Common Conditions. Kampala, Uganda: Uganda Ministry of Health.

89. Wipasa J, Okell L, Sakkhachornphop S, Suphavitai C, Chawansuntati K, et al. (2011) Short-lived IFN-gamma effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. *PLoS pathogens* 7: e1001281.
90. Horowitz A, Newman KC, Evans JH, Korbel DS, Davis DM, et al. (2010) Cross-talk between T cells and NK cells generates rapid effector responses to *Plasmodium falciparum*-infected erythrocytes. *J Immunol* 184: 6043–6052.
91. Maecker HT, Trotter J (2006) Flow cytometry controls, instrument setup, and the determination of positivity. *Cytometry Part A* 69: 1037–1042.
92. Lamoreaux L, Roederer M, Koup R (2006) Intracellular cytokine optimization and standard operating procedure. *Nat Protoc* 1: 1507–1516.
93. McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, et al. (2008) Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. *Cytometry Part A* 73: 400–410.
94. Roederer M, Nozzi JL, Nason MX (2011) SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. *Cytometry Part A* [Epub ahead of print].